René Russo has been appointed CEO of Akrevia Therapeutics. She is also joining the Cambridge, MA, company’s board of directors. Russo was most recently CEO of Arsanis (NASDAQ: [[ticker:ASNS]]), a biotech that combined operations with X4 Pharmaceuticals in a reverse merger earlier this year. Launched last year with $30 million in financing, Akrevia is developing cancer immunotherapies intended to hit tumors in a more targeted way.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
